(SILO)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Name | Position |
|---|---|
| Mr. Daniel E. Ryweck | Chief Financial Officer |
| Mr. Eric Weisblum | Chairman, President & CEO |
| Date | Type | Document |
|---|---|---|
| 2025-12-29 | 8-K | ea0271073-8k_silopharma.htm |
| 2025-11-13 | 10-Q | ea0264107-10q_silo.htm |
| 2025-10-29 | S-1 | ea0262498-s1_silo.htm |
| 2025-10-24 | 8-K | ea0262461-8k_silopharma.htm |
| 2025-10-01 | 8-K | ea0259464-8k_silo.htm |
| 2025-09-05 | DEF 14A | ea0255705-def14a_silo.htm |
| 2025-08-25 | PRE 14A | ea0253999-pre14a_silo.htm |
| 2025-08-13 | 10-Q | ea0252531-10q_silopharma.htm |
| 2025-08-05 | 8-K | ea0251774-8k_silo.htm |
| 2025-07-29 | 8-K | ea0250629-8k_silo.htm |